Trademark applications and grants for Bioinvent I N T Ab. Bioinvent I N T Ab has 7 trademark applications. The latest application filed is for "a symbol or image mark"
Patent Application | Date |
---|---|
ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS 20220259309 - 17/627385 FRENDEUS; Bjorn ;   et al. | 2022-08-18 |
NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES 20220073634 - 17/290352 FRENDEUS; Bjorn ;   et al. | 2022-03-10 |
NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF 20220041723 - 17/272740 FRENDEUS; Bjorn ;   et al. | 2022-02-10 |
NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES 20220002426 - 17/290340 FRENDEUS; Bjorn ;   et al. | 2022-01-06 |
NOVEL COMBINATION AND USE OF ANTIBODIES 20200362036 - 16/959425 Frendeus; Bjorn ;   et al. | 2020-11-19 |
NCAGE Code | A169N | BIOINVENT INTERNATIONAL AB |
NCAGE Code | SGE73 | BIOINVENT INTERNATIONAL AB |
CAGE Code | SGE73 | BIOINVENT INTERNATIONAL AB |
CAGE Code | A169N | BIOINVENT INTERNATIONAL AB |
S.A.M. Registration | A169N [559765847] | BIOINVENT INTERNATIONAL AB |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.